Indication & Dosage :
Blincyto (Blinatumomab), is a prescription medicine used to treat of of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL), including patients in first or second complete remission with minimal residual disease (≥0.1%), those with relapsed or refractory disease, and patients with Philadelphia chromosome-negative ALL during the consolidation phase of multiphase chemotherapy. Blincyto manufacturted by AMGEN Pharma Ltd. In USA.
Blinatumomab is administered as a continuous 24-hour intravenous infusion via a pump, typically once per treatment cycle, under the supervision of a physician. Initial monitoring is recommended during the first 1–2 days to ensure patient safety.
Side Effects :
The most common side effects of Blinatumomab are:
Fever, Headache, tremor, chills, Infusion, Cytopenias.
The above information comes from the Internet. Please consult with doctor for medical advice.
Suggestion :
* Any advice on the use of the drug is for reference only. Please consult with doctor for medical advice. All Names, logos, trademarks are property of their respective owners. Watermarks, QR code used for identification purposes only.
